Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Overview 10 Therapeutics Development 11 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Stage of Development 11 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Therapy Area 12 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Indication 13 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Companies 17 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Universities/Institutes 22 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment 24 Assessment by Monotherapy/Combination Products 24 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 29 Acetylon Pharmaceuticals, Inc. 29 Chong Kun Dang Pharmaceutical Corp. 31 HitGen LTD 32 Kancera AB 33 Karus Therapeutics Limited 34 Lycera Corp. 35 Merck & Co., Inc. 36 Millennium Pharmaceuticals, Inc. 37 OncoHoldings, Inc. 38 Quimatryx, S.L. 39 Sigma-Tau S.p.A. 40 SK Biopharmaceuticals Co., Ltd. 41 Takeda Pharmaceutical Company Limited 42 TetraLogic Pharmaceuticals 43 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles 44 ACY-241 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ACY-738 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 ACY-775 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 C-1A - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 CKD-506 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 CKD-L - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Drugs to Inhibit HDAC6 for Oncology - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 HG-3001 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 IKH-12 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 KA-2507 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 KAN-0439221 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 KAN-439782 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 KAR-3000 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 N-140 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 ONCO-101 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 QTX-100 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 QTX-102 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 QTX-125 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 remetinostat - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 ricolinostat - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecule to Inhibit HDAC6 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Small Molecules to Inhibit HDAC6 for Autoimmune Diseases - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 ST-3595 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 vorinostat - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Projects 88 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Featured News & Press Releases 90 Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 90 Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 91 Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma 92 Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma 94 Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models 96 Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 98 Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma 98 Apr 22, 2015: Acetylon Presents Data on Synergistic Activity of Selective HDAC6 Inhibition in Preclinical Models of Multiple Myeloma and Mantle Cell Lymphoma at the American Association for Cancer Research Annual Meeting 99 Jan 21, 2015: Acetylon Presents at the Wells Fargo Celgene Partnership Forum 100 Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma 101 Dec 09, 2014: Acetylon Pharmaceuticals Announces Ricolinostat Continues to Demonstrate Clinically Meaningful and Durable Disease Response Rates in Phase 1b Combination Studies in Multiple Myeloma 101 Dec 04, 2014: Acetylon Pharmaceuticals Initiates Phase 2 Study of Ricolinostat (ACY-1215) in Combination with Pomalyst 103 Dec 01, 2014: Acetylon’s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition 103 Jun 13, 2014: Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) is Active and Well-tolerated in Ongoing Phase 1b Studies in Patients with Refractory Multiple Myeloma at the 19th Congress of the EHA 107 May 28, 2014: TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting 108 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110

List of Tables Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Development by Companies, H1 2016 (Contd..2) 20 Products under Development by Companies, H1 2016 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H1 2016 22 Products under Investigation by Universities/Institutes, H1 2016 23 Assessment by Monotherapy/Combination Products, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 28 Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 29 Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 31 Pipeline by HitGen LTD, H1 2016 32 Pipeline by Kancera AB, H1 2016 33 Pipeline by Karus Therapeutics Limited, H1 2016 34 Pipeline by Lycera Corp., H1 2016 35 Pipeline by Merck & Co., Inc., H1 2016 36 Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 37 Pipeline by OncoHoldings, Inc., H1 2016 38 Pipeline by Quimatryx, S.L., H1 2016 39 Pipeline by Sigma-Tau S.p.A., H1 2016 40 Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 41 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 42 Pipeline by TetraLogic Pharmaceuticals, H1 2016 43 Dormant Projects, H1 2016 88 Dormant Projects (Contd..1), H1 2016 89 List of Figures Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Top 10 Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 24 Number of Products by Stage and Mechanism of Actions, H1 2016 25 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28

Acetylon Pharmaceuticals, Inc. Chong Kun Dang Pharmaceutical Corp. HitGen LTD Kancera AB Karus Therapeutics Limited Lycera Corp. Merck & Co., Inc. Millennium Pharmaceuticals, Inc. OncoHoldings, Inc. Quimatryx, S.L. Sigma-Tau S.p.A. SK Biopharmaceuticals Co., Ltd. Takeda Pharmaceutical Company Limited TetraLogic Pharmaceuticals